Form 4 Filing for Mineralys Therapeutics, Inc.

David Malcom, Chief Medical Officer of Mineralys Therapeutics, Inc., reported transactions on July 17, 2026. He acquired 416 shares of Common Stock at $15.44 per share and disposed of 416 shares of Common Stock at $26.53 per share. Concurrently, he exercised a stock option for 416 shares of Common Stock at an exercise price of $15.44, with the option vesting per a schedule detailed in footnote F2. These transactions were executed under a Rule 10b5-1 trading plan. Following these transactions, Malcom holds 51,800 shares directly and has 3,334 shares underlying vested options.